熱門資訊> 正文

Jazz Pharmaceuticals与Saniona达成独家许可协议

2025-08-20 20:23

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Saniona on Wednesday announced a global license agreement between the two companies.
Under the deal, Jazz (NASDAQ:JAZZ) will obtain exclusive worldwide rights to develop and commercialize preclinical asset SAN2355 in epilepsy and other potential indications, the companies said.
Jazz will lead and fund all further development, regulatory submissions, and global commercialization efforts.
Saniona to receive $42.5 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales.

More on Jazz Pharmaceuticals

Jazz Pharmaceuticals plc 2025 Q2 - Results - Earnings Call Presentation
Jazz Pharmaceuticals plc (JAZZ) Q2 2025 Earnings Call Transcript
Jazz Pharmaceuticals: I See Big Potential In This Stock As An Investor
Jazz Pharma wins FDA nod for Modeyso against rare brain tumor
Jazz Pharmaceuticals projects late Q4 zanidatamab Phase III data, signals leadership transition and updates 2025 guidance

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。